US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises
Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesity
Faced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and public employees have now started to restrict or eliminate coverage.
The pullback stems from the dramatic increase in public spending on drugs such as Ozempic and Wegovy in recent years.
https://www.theguardian.com/us-news/2026/apr/14/states-medicaid-coverage-glp-1">Continue reading...Wegovy major changes for patients
- Wegovy major change from April 14 for certain people using jab to lose weight Mirror —
- Triple-strength Wegovy 'mega dose' given green light by health officials allowing users to shed 'significantly more weight' with a single injection Daily Mail —
- Five key weight loss jab side effects reported by 43 percent of patients Mirror —
- UK approves Novo Nordisk single-dose 7.2mg Wegovy pen for obesity patients Seeking Alpha —
- Thousands are sharing side effects of weight-loss drugs doctors may miss, study suggests CTV News —